Category: Healthcare

AIHealthcareStartups

Medical AI Firm OpenEvidence Secures $200M Funding Amid Industry Scrutiny of AI Claims

Medical AI startup OpenEvidence has reportedly secured $200 million in new funding, doubling its valuation to $6 billion. The funding announcement comes amid growing industry scrutiny of AI capability claims, with experts questioning marketing assertions from major technology firms.

Medical AI Startup Valuation Soars

OpenEvidence, which develops an ad-supported AI chatbot for medical practitioners, has reportedly raised $200 million at a $6 billion valuation, according to recent funding reports. This represents a significant increase from the company’s $3.5 billion valuation following a $210 million round in July, sources indicate. The rapid valuation growth highlights continued investor enthusiasm for healthcare artificial intelligence solutions despite broader market challenges.

by Natalie Brooks
BusinessHealthcare

Novo Nordisk’s Patent Lapse Opens Door for Generic GLP-1 Competition in Canadian Market

In a surprising regulatory development, Novo Nordisk allegedly failed to maintain patent protection for its blockbuster drug semaglutide in Canada. The oversight could enable generic competition years earlier than expected in one of the world’s largest markets for the GLP-1 medication.

Patent Maintenance Oversight Creates Generic Drug Opportunity

In what industry analysts are calling a remarkable regulatory oversight, pharmaceutical company Novo Nordisk reportedly allowed its patent for the popular diabetes and weight loss drug semaglutide to lapse in Canada by failing to pay maintenance fees, according to recent reports. The situation came to light during an interview with Sandoz CEO Richard Saynor, who revealed his company plans to launch a generic version of the GLP-1 drug in Canada as early as 2026.

by Darren Holt